Duvie (lobeglitazone) / Chong Kun Dang 
Welcome,         Profile    Billing    Logout  
 12 Diseases   7 Trials   7 Trials   180 News 


123»
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Enrollment open:  Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults (clinicaltrials.gov) -  Jul 28, 2025   
    P1,  N=24, Recruiting, 
    The addition of lobeglitazone in patients with type 2 diabetes inadequately controlled with metformin and sitagliptin is a beneficial therapeutic option, not only providing effective glycaemic control but also improving insulin function such as sensitivity and enhancing certain lipid parameters. Not yet recruiting --> Recruiting
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Review, Journal:  Lobeglitazone and Its Therapeutic Benefits: A Review. (Pubmed Central) -  Jan 8, 2024   
    Side effects of lobeglitazone included peripheral edema, weight gain, and bone mineral density, which did not require hospitalization for these effects. This article
  • ||||||||||  rivoglitazone (CS-011) / Daiichi Sankyo, Santen
    Retrospective data, Journal:  Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis. (Pubmed Central) -  Oct 24, 2023   
    Severe adverse events with standard-dose [RR1.88 (95%CI: 0.69-5.12);P = 0.22;I = 0%] and high-dose [RR 1.27 (95% CI: 0.45 - 3.59); P = 0.68; I = 0%] rivoglitazone was comparable to placebo. This meta-analysis highlights the good glycaemic efficacy and safety of both standard and high-dose rivoglitazone, and appears to be better than lobeglitazone in T2DM.
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Journal:  Thiazolidinediones: Recent Development in Analytical Methodologies. (Pubmed Central) -  Aug 4, 2023   
    The specified outcomes followed extensive learning, and the most recent advances in analytical methods for the identification of pioglitazone, pioglitazone HCl, rosiglitazone, rosiglitazone maleate and lobeglitazone were reviewed. Additionally, this article briefly discusses features of analytical discovery on thiazolidinediones, which will enable readers to access all discoveries in one place with precise outcomes.
  • ||||||||||  CKD-393 / Chong Kun Dang
    Trial completion:  Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 (clinicaltrials.gov) -  Jun 9, 2023   
    P1,  N=33, Completed, 
    Additionally, this article briefly discusses features of analytical discovery on thiazolidinediones, which will enable readers to access all discoveries in one place with precise outcomes. Not yet recruiting --> Completed
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang, efatutazone (CS-7017) / Daiichi Sankyo
    Journal:  In-silico discovery of inhibitors against human papillomavirus E1 protein. (Pubmed Central) -  Jun 26, 2022   
    The binding free energies for Cinalukast, Lobeglitazone, and Efatutazone were -37.84 kcal/mol, -25.30 kcal/mol, and -29.89 kcal/mol respectively. Therefore, we propose their chemical scaffolds for future rational design of E1 inhibitors.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    PK/PD data, Journal:  Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. (Pubmed Central) -  Apr 30, 2022   
    The geometric mean ratio (GMR; 90% confidence interval [CI]) for maximum concentration (C ) and area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC ) of lobeglitazone was 1.06 (0.90-1.24) and 1.07 (0.82-1.40), respectively, for mild HI vs control A. The GMR (90%CI) of C and AUC was 0.70 (0.56-0.88) and 1.00 (0.72-1.37), respectively, for moderate HI vs control B. For M7, the GMR (90%CI) of C and AUC was 1.09 (0.75-1.57) and 1.18 (0.71-1.97), respectively, for mild HI vs control A and 1.50 (0.95-2.38) and 1.79 (1.06-3.04), respectively, for moderate HI vs control B. Notable adverse events or tolerability issues were not observed. Lobeglitazone may be safely used in patients with mild or moderate HI without dose adjustment.
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Preclinical, Journal:  Effect of Lobeglitazone on motor function in Rat Model of Parkinson's Disease with Diabetes Co-morbidity. (Pubmed Central) -  Mar 9, 2022   
    Furthermore, lobeglitazone (1 mg/kg) reversed, in substantia nigra and striatum, the changes in tyrosine hydroxylase, TNF-α, NF-κB and PPAR-γ receptor content induced by rotenone in rats with diabetic condition. Although other preclinical studies are needed, these findings suggest that lobeglitazone is a promising neuroprotective candidate for clinical trials for PD patients with diabetes co-morbidity.
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang, efpeglenatide (HM11260C) / Sanofi, tirzepatide (LY3298176) / Eli Lilly
    FDA event, Review, Journal:  Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales. (Pubmed Central) -  Feb 8, 2022   
    Furthermore, there are several interesting alternatives, such as lobeglitazone, efpeglenatide and tirzepatide, in ongoing clinical trials...The large heterogeneity of T2DM is also creating a push towards more personalized and accessible treatments. We describe several interesting alternatives in ongoing clinical trials, which may help to achieve this in the near future.
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang
    Trial completion, Trial completion date, Trial primary completion date:  Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie (clinicaltrials.gov) -  Jan 20, 2022   
    P4,  N=159, Completed, 
    KEY MESSAGES. Not yet recruiting --> Completed | Trial completion date: Dec 2020 --> Sep 2021 | Trial primary completion date: Dec 2020 --> Aug 2021
  • ||||||||||  Duvie (lobeglitazone) / Chong Kun Dang, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
    Trial completion, Combination therapy:  Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy (clinicaltrials.gov) -  Jan 4, 2022   
    P4,  N=78, Completed, 
    Not yet recruiting --> Completed | Trial completion date: Dec 2020 --> Sep 2021 | Trial primary completion date: Dec 2020 --> Aug 2021 Active, not recruiting --> Completed